Pre-made Certolizumab benchmark antibody ( Fab, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-¦Á) and is manufactured by UCB.
| Products Name (INN Index) | Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
|---|---|
| INN Name | Certolizumab |
| Target | TNF |
| Format | Fab |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5wuv:HL/5wux:HL:AB:CD |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | UCB |
| Conditions Approved | Ankylosing spondylitis,Crohn's disease,Plaque psoriasis,Psoriatic arthritis,Rheumatoid arthritis,Spondylitis,Non-radiographic axial spondyloarthritis |
| Conditions Active | Interstitial cystitis,Juvenile rheumatoid arthritis |
| Conditions Discontinued | Cognition disorders |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFA/TNF |
| Package |
